Global Oncology Academy
The Global Oncology Academy (GOA) is an educational platform for physicians and other healthcare professionals involved in oncology. Its mission is to increase knowledge regarding the disease course of specific cancers and address key elements for successful management. The GOA series will also share the science around innovations in combination therapies, oncology strategies, and new developments.
For more information about GOA, visit www.globaloncologyacademy.org.
76-90 of 422
Managing Immunotherapy Toxicities in Lung Cancer Patients
Spotlight on Lung CancerManaging Immunotherapy Toxicities in Lung Cancer Patients
Jacob Sands, MD
Aliyah Pabani, MD
Redefining Cancer Care with Functional Precision Medicine
Project Oncology®Redefining Cancer Care with Functional Precision Medicine
Matt Birnholz, MD
Jim Foote, MBA
Screening Modalities for Colon Cancer: What You Need to Know
GI InsightsScreening Modalities for Colon Cancer: What You Need to Know
Peter Buch, MD, FACG, AGAF, FACP
Aasma Shaukat, MD, MPH
Optimizing cGVHD Treatment Decisions in the Second- and Third-Line Settings
Project Oncology®Optimizing cGVHD Treatment Decisions in the Second- and Third-Line Settings
Charles Turck, PharmD, BCPS, BCCCP
Stephanie Gregory, CNP
Managing Immune-Related Adverse Events in Metastatic NSCLC
Project Oncology®Managing Immune-Related Adverse Events in Metastatic NSCLC
Charles Turck, PharmD, BCPS, BCCCP
Paul Bunn, MD
Survival Outcomes in Squamous Cell Carcinoma of the Anal Canal: POD1UM-303 Data
Project Oncology®Survival Outcomes in Squamous Cell Carcinoma of the Anal Canal: POD1UM-303 Data
Brian P. McDonough, MD, FAAFP
Stacey Cohen, MD
- advertisement
Optimizing First-Line Care for PD-L1–Low Metastatic NSCLC
Project Oncology®Optimizing First-Line Care for PD-L1–Low Metastatic NSCLC
Charles Turck, PharmD, BCPS, BCCCP
Deepa Rangachari, MD
Managing High-Risk Subgroups in Metastatic NSCLC
Project Oncology®Managing High-Risk Subgroups in Metastatic NSCLC
Charles Turck, PharmD, BCPS, BCCCP
Melina Marmarelis, MD
Deepa Rangachari, MD
Communicating Pathologic Response Results in Resectable NSCLC
Project Oncology®Communicating Pathologic Response Results in Resectable NSCLC
Charles Turck, PharmD, BCPS, BCCCP
Alexander Spira, MD, PhD, FACP
Robert Merritt, MD
Real-World Strategies for Complex cGVHD Treatment Decisions
Project Oncology®Real-World Strategies for Complex cGVHD Treatment Decisions
Brian P. McDonough, MD, FAAFP
Doris M. Ponce, MD, MS
Interpreting Perioperative Trial Designs in Resectable NSCLC Research
Project Oncology®Interpreting Perioperative Trial Designs in Resectable NSCLC Research
Charles Turck, PharmD, BCPS, BCCCP
Laura Alder, MD
Christine Bestvina, MD
Shared Decision-Making in Colorectal Cancer Screening
Clinician's RoundtableShared Decision-Making in Colorectal Cancer Screening
Gates B. Colbert, MD
Sarina Schrager, MD
Lashika Yogendran, MD
- advertisement
Emerging Therapeutic Strategies in Metastatic NSCLC
Project Oncology®Emerging Therapeutic Strategies in Metastatic NSCLC
Brian P. McDonough, MD, FAAFP
Urs Weber, MD
Turning Cold Tumors Hot with mRNA COVID-19 Vaccines
COVID-19: On The FrontlinesTurning Cold Tumors Hot with mRNA COVID-19 Vaccines
Hallie Blevins, PhD
Marlene Mimi Maeusli, PhD.
Navigating AKT Inhibitor-Associated Adverse Events in HR+/HER2- Advanced Breast Cancer
Project Oncology®Navigating AKT Inhibitor-Associated Adverse Events in HR+/HER2- Advanced Breast Cancer
Alexandria May, PharmD, BCPS
Adam Brufsky, MD, PhD
